Thomas Steyer’s United Therapeutics UTHR Stock Holding History

Thomas Steyer’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$287K	–	162
2025 Q2	$287K	Hold	1,000	–	–	﹤0.01%	103
2025 Q1	$308K	Hold	1,000	–	–	﹤0.01%	106
2024 Q4	$353K	Hold	1,000	–	–	﹤0.01%	106
2024 Q3	$358K	Sell	1,000 -142,000	-99%	-$48M	﹤0.01%	116
2024 Q2	$45.6M	Buy	143,000 +33,000	+30%	+$8.73M	0.2%	62
2024 Q1	$25.3M	Sell	110,000 -366,000	-77%	-$82.6M	0.11%	67
2023 Q4	$105M	Buy	+476,000	New	+$110M	0.48%	45
2023 Q3	–	Sell	-193,267	Closed	-$42.7M	–	176
2023 Q2	$42.7M	Sell	193,267 -471,500	-71%	-$104M	0.21%	70
2023 Q1	$149M	Buy	664,767 +8,894	+1%	+$2.19M	0.81%	41
2022 Q4	$182M	Buy	655,873 +106,200	+19%	+$26.8M	1.08%	34
2022 Q3	$115M	Buy	549,673 +156,977	+40%	+$35.1M	0.63%	49
2022 Q2	$92.5M	Buy	392,696 +13,000	+3%	+$2.64M	0.5%	54
2022 Q1	$68.1M	Buy	379,696 +58,936	+18%	+$11.2M	0.33%	64
2021 Q4	$69.3M	Buy	+320,760	New	+$63M	0.35%	56
2020 Q3	–	Sell	-350,000	Closed	-$42.4M	–	136
2020 Q2	$42.4M	Sell	350,000 -15,000	-4%	-$1.69M	0.34%	62
2020 Q1	$34.6M	Buy	+365,000	New	+$34.7M	0.3%	51

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Thomas Steyer's UTHR Position: Q3 2025 in Review

Thomas Steyer sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 1,000 shares — an estimated $287K sold.

Thomas Steyer first reported a position in UTHR in Q1 2020 and held it in 16 quarters. The position peaked at $182M in Q4 2022. 708 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

Thomas Steyer reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
Thomas Steyer sold 1,000 United Therapeutics shares in Q3 2025, an estimated $287K.
Thomas Steyer first reported a position in United Therapeutics in Q1 2020 and held it in 16 quarters.
Thomas Steyer's United Therapeutics position peaked at $182M in Q4 2022.
708 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.